Clinical value of 24-hour delayed imaging in somatostatin receptor scintigraphy for meningioma

Journal of Nuclear Medicine

Volumn 40, Issue 8, 1999, Pages 1246-1251

  Klutmann, Susanne ^b   Bohuslavizki, Karl H ^a   Tietje, Nicole ^b   Kröger, Sabine ^b   Behnke, Anja ^b   Brenner, Winfried ^b   Mester, Janos ^b   Henze, Eberhard ^b   Clausen, Malte ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b NONE

Author keywords

111In octreotide; Delayed imaging; Meningioma; Somatostatin receptor scintigraphy

Indexed keywords

PENTETREOTIDE IN 111; SOMATOSTATIN RECEPTOR;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; FEMALE; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MENINGIOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SCINTIGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR LOCALIZATION; TUMOR VOLUME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; INDIUM RADIOISOTOPES; MAGNETIC RESONANCE IMAGING; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; OCTREOTIDE; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0032821340     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Reubi JC, Krenning E, Lamberts SWJ, Kvols L. In vitro detection of somatostatin receptors in human tumors. Digestion. 1993;54(suppl 1):76-83.
2. Haldemann AR, Rösler H, Barth A, et al. Somatostatin receptor scintigraphy in central nervous system tumors: role of blood-brain barrier permeability. J Nucl Med. 1995;36:403-410.
3. Hildebrandt G, Scheidhauer K, Luyken C, et al. High sensitivity of the in vivo detection of somatostatin receptors by indium-[DTPA-octreotide]-scintigraphy in meningioma patients. Acta Neurochir Wien. 1994;126:63-71.
4. Schmidt M, Scheidhauer K, Luyken C, et al. Somatostatin receptor imaging in intracranial tumours. Eur J Nucl Med. 1998;25:675-686.
5. Bohuslavizki KH, Brenner W, Braunsdorf WEK, et al. Somatostatin receptor scintigraphy in differential diagnosis of meningioma. Nucl Med Commun. 1996;17:302-310.
6. Jochens R, Cordes M, Wolters A, et al. Investigations of brain tumors and brain metastases using [In-DTPA-D-Phe]-octreotide-SPECT [in German]. Klin Neurorad. 1995;5:1-13.
7. Lamberts SW, Krenning EP, Bakker WH, Breemann WAP, Kooij PPM. Somatostatin receptor imaging in the diagnosis of pituitary and parasellar tumors. In: Melmed S, Robbings RJ, eds. Molecular and Advances in Pituitary Disorders. Berlin, Germany: Blackwell Science Publishing; 1991:285-292.
8. Bohuslavizki KH, Behnke A, Brenner W, et al. Value of somatostatin receptor scintigraphy in patients with suspected meningioma as compared to MRI [abstract]. J Nucl Med. 1996;37:257P.
9. Klutmann S, Bohuslavizki KH, Brenner W, et al. Impact of somatostatin receptor scintigraphy in postsurgical follow-up of patients with meningioma [abstract]. J Nucl Med. 1998;39:38P.
10. Klutmann S, Bohuslavizki KH, Brenner W, et al. Somatostatin receptor scintigraphy in postsurgical follow-up examinations of meningioma. J Nucl Med. 1998;39:1913-1917.
11. Jamar F, Fiasse R, Leners N, Pauwels S. Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: safety, efficacy and impact on patient management. J Nucl Med. 1995;36:542-549.
12. Luyken C, Hildebrandt G, Scheidhauer K, Krisch B. Diagnostic value of somatostatin receptor scintigraphy in patients with intracranial masses [in German]. Nuklearmedizin. 1993;16:317-324.
13. Maini CL, Cioffi RP, Tofani A, et al. Indium-111-octreotide scintigraphy in neurofibromatosis. Eur J Nucl Med. 1995;22:201-206.
14. Scheidhauer K, Hildebrandt G, Luyken C, Schomäcker K, Klug N, Schicha H. Somatostatin receptor scintigraphy in brain tumors and pituitary tumors: first experiences. Horm Metab Res. 1993;27:59-62.
15. Nauck C, Ivancevic V, Emrich D, Creutzfeldt W. In-111-pentetreotide scintigraphy as an imaging procedure for endocrine gastro-entero-pancreatic tumors. Z Gastroenterol. 1994;32:323-327.
16. Bohuslavizki KH, Brenner W, Tietje N, et al. Is a 4-hour protocol of somatostatin receptor scintigraphy sufficient in patients suspected for meningioma [abstract]? Eur J Nucl Med. 1997;24:859.
17. 3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20:716-731.
18. Bohuslavizki KH, Brenner W, Behnke A, et al. Impact of 24-h images of somatostatin receptor scintigraphy in patients suspected for meningioma [abstract, in German]. Nuklearmedizin. 1997;36:A5.
19. Joseph K, Stapp J, Reinecke J, et al. Receptor scintigraphy in endocrine gastroenteropancreatic tumors [in German]. Dtsch Med Wochenschr. 1992;117: 1025-1028.
20. 111In-pentreotide in gastroenteropancreatic tumors [in German]. Nuklearmedizin. 1993;32:299-305.
21. Bach D, Adrian HJ, Eisenhut M, Dörr U, Bihl H. Biodistribution and pharmacokinetics of radiolabeled somatostatin analogs [in German]. Nuklearmedizin. 1993;16: 269-280.
22. Reubi JC, Horisberger U, Lang W, Koper JW, Braakman R, Lamberts SWJ. Coincidence of EGF receptors and somatostatin receptors in meningiomas but inverse, differentiation-dependent relationship in glial tumors. Am J Pathol. 1989;134:337-344.
23. Reubi JC, Maurer R, Klijn JGM, et al. High incidence of somatostatin receptors in human meningiomas: biochemical characterization. J Clin Endocrinol Metab. 1986;63:433-438.
24. Maini CL, Tofani A, Sciuto R, Carapella C, Cioffi R, Crecco M. Scintigraphy visualization of somatostatin receptors in human meningiomas using 111-indium-DTPA-D-Phe-1-octreotide. Nucl Med Commun. 1993;14:505-508.
25. Sachs L. Applied Statistics: A Handbook of Techniques. 2nd ed. New York, NY: Springer; 1984.